Anticytokine therapy for osteoarthritis

Bibliography

• HAMERMAN D: Aging and osteoarthritis: basic mechanisms. J. Am. Cedar Soc. (1993) 41:760–770.
   Web of Science ®Google Scholar
• PELLETIER J-P, MARTEL-PELLETIER J, HOWELL DS: Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions: A Textbook of Rheumatology Koopman WJ (Ed.), Williams and Wilkins, Baltimore (1997):1969–1984.
   Google Scholar
• POOLE AR: Cartilage in Health and Disease. In: Arthritis am Allied Conditions: A Textbook of Rheumatology Koopman WJ (Ed.), Williams and Wilkins, Baltimore (1997):255–308.
   Google Scholar
• SANDELL LJ, AIGNER T: Articular cartilage and changes in arthritis. An introduction: cell Biology of osteoarthritis. Arthritis Res. (2001) 3:107–113.
   Google Scholar
• CHIKANZA IC, FERNANDES L: Recent developments in the treatment of osteoarthritis. Expert Opirr. Investig. Drugs (1999) 4:273–290.
   Google Scholar
• FELSON DT, LAWRENCE RC, HOCHBERG MC et al.: Osteoarthritis: new insights. Part 2: treatment approaches. Ann. Intern. Med. (2000) 133:726–737.
   Google Scholar
• SHAMOON M, HOCHBERG MC: Treatment of osteoarthritis with acetaminophen: efficacy, safety, and comparison with nosteroidal anti- inflammatory drugs. Curr. Rheumatol. Rep. (2000) 2:454–458.
   PubMedGoogle Scholar
• TIVE L: Celecoxib clinical profile. Rheumatol. (2000) 39\(Suppl. 2):21–28.
   Google Scholar
• MCKENNA F, BORENSTEIN D, WENDT H, WALLEMARK C, LEFKOWITH JB, GEIS GS: Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scam/. Rheumatol. (2001) 30:11–18.
   PubMed Web of Science ®Google Scholar
• REGINSTER JY, GILLOT VV, BRUYERE 0, HENROTIN Y: Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Curr. Rheumatol. Rep. (2000) 2:472–477.
   PubMedGoogle Scholar
• REGINSTER JY, DEROISY R, ROVATI LC et al.: Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet (2001) 357:251–256.
   PubMed Web of Science ®Google Scholar
• OEGEMA TRJ, DELORIA LB, HART DA: Oral glucosamine enhances chondroitin sulfate levels in articular cartilage after a chymopapain injury. Orthopaed. Trans.(2001) 26:663.
   Google Scholar
• POOLE AR: An introduction to the pathophysiology of osteoarthritis. Frontiers Biosci. (1999) 4:D662–670.
   PubMedGoogle Scholar
• •This recent review and other papers in this volume provide an excellent overview of the field and may be read online at http:// www.bioscience.org/ 191999/v4/d.
   Google Scholar
• THONAR EJ-M, LENZ ME, MASUDA K, MANICOURT D-H: Body fluid markers of cartilage metabolism. In: Dynamics of bone and cartilage metabolism. Seibel MJ, Robins SP, Bilezekian JP (Eds.) Academic Press, New York (1999):453–464.
   Google Scholar
• GARNERO P, ROUSSEAU J-C, DELMAS PD: Molecular basis and clinical use of biochemical markers of bone, cartilage and synovium in joint diseases. Arthritis Rheum.(2000) 43:953–968.
   PubMed Web of Science ®Google Scholar
• OTTERNESS IG, SWINDELL AC, ZIMMERER RO, POOLE AR, IONESCU M, WEINER E: An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage (2000) 8:180–185.
   PubMed Web of Science ®Google Scholar
• POOLE AR: NIH white paper: Biomarkers, the osteoarthritis initiative. (2000).
   Google Scholar
• ••This is part of the report from theOsteoarthritis Initative Steering Group held on February 28–29, 2000 at the NIH, which may be read online at http:// www.nih.goviniams/news/oisg/.
   Google Scholar
• VIGNON E, GARNERO P, DELMAS P et al.: Recommendations for the registration of drugs used in the treatment of osteoarthritis: an update on biochemical markers. Osteoarthritis Cartilage (2001) 9:289–293.
   PubMed Web of Science ®Google Scholar
• WATSON PJ, HALL LD, MALCOLM A, TYLER JA: Degenerative joint disease in the guinea pig. Use of magnetic resonance imaging to monitor progression of bone pathology. Arthritis Rheum. (1996) 39:1327–1337.
   Google Scholar
• BURSTEIN D, BASHIR A, GRAY ML: MRI techniques in early stages of cartilage disease. Invest. Radial (2000) 35:622–638.
   PubMed Web of Science ®Google Scholar
• TETLOW LC, ADLAM DJ, WOOLLEY DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage. Arthritis Rheum. (2001) 44:585–594.
   PubMed Web of Science ®Google Scholar
• HOMANDBERG GA: Potential regulation of cartilage metabolism in osteoarthritis by fibronectin fragments. Frontiers Biosci. (1999) 4:D713–730.
   PubMedGoogle Scholar
• GOLDRING MB: The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Conner. Tiss. Res. (1999) 40:1–11.
   PubMed Web of Science ®Google Scholar
• GOLDRING MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum. (2000) 43:1916–1926.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA, MOLDAWER LL: Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis: a primer for clinicians. Amgen, Inc., Thousand Oaks, CA (2000).
   Google Scholar
• ••This excellent compendium and otherresources on the role of cytokines in arthritis may be ordered online at www.interleultin-1.com.
   Google Scholar
• NAKAMURA H, YOSHINO S, KATO T, TSURUHA J, NISHIOKA K: T-cell mediated inflammatory pathway in osteoarthritis. Osteoarthritis Cartilage (1999) 7:401–402.
   PubMed Web of Science ®Google Scholar
• PETTIT AR, AHERN MJ, ZEHNTNER S, SMITH MD, THOMAS R: Comparison of differentiated dendritic cell infiltration of autoimmune and osteoarthritis synovial tissue. Arthritis Rheum. (2001) 44:105–110.
   PubMed Web of Science ®Google Scholar
• AURON PE: The interleukin 1 receptor: Ligand interactions and signal transduction. Cytakine Growth Factor Rev. (1998) 9:221–237.
   PubMed Web of Science ®Google Scholar
• •Excellent review of structure-function relationships of IL-1 ligands and receptors.
   Google Scholar
• BURGER D, CHICHEPORTICHE R, GIRI JG, DAYER J-M: The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by Type II interleukin-1 soluble receptor and hindered by Type I interleukin-1 soluble receptor. J. Clin. Invest. (1995) 96:38–41.
   PubMed Web of Science ®Google Scholar
• AREND WE MALYAK M, GUTHRIDGE CJ, GABAY C: Interleukin-1 receptor antagonist: role in biology. Ann. Rev Immune]. (1998) 16:27–55.
   PubMed Web of Science ®Google Scholar
• ••Review of IL-1Ra structure and function.
   Google Scholar
• WESTACOTT CI, BARAKAT AF, WOOD L et al.: Tumor necrosis factor alpha can contribute to focal loss of cartilage in osteoarthritis. Osteoarthritis & Cartilage (2000) 8:213–221.
   PubMed Web of Science ®Google Scholar
• PATEL IR, ATTUR MG, PATEL RN et al: TNF-a convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-a. J. Immune]. (1998) 160:4570–4579.
   PubMed Web of Science ®Google Scholar
• FELDMAN M, BONDESON J, BRENNAN FM, FOXWELL BMJ, MAINI RN: The rationale for the current boom in anti-TNFa treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFa and minimize hazards? Ann. Rheum. Dis. (1999) 58 (Suppl. B:I27431.
   Google Scholar
• FELL HB, JUBB RW: The effect of synovial tissue on the breakdown of articular cartilage in organ culture. Arthritis Rheum. (1977) 20:1359–1371.
   PubMed Web of Science ®Google Scholar
• •First report of IL-1 as a catabolic factor for cartilage.
   Google Scholar
• DINGLE JT, SAKLATVALA J, HEMBRY R, TYLER J, FELL HB, JUBB R: A cartilage catabolic factor from synovium. Biochem. J. (1979) 184:177–180.
   PubMed Web of Science ®Google Scholar
• DAYER J-M, RUSSELL RGG, KRANE SM: Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science (1977) 195:181–183.
   PubMed Web of Science ®Google Scholar
• •First report of IL-1 as inducer of metalloproteinase production by rheumatoid synovial fibroblasts.
   Google Scholar
• MEATS JE, MCGUIRE MB, RUSSELL RGG: Human synovium releases a factor which stimulates chondrocyte production of PGE and plasminogen activator. Nature (1980) 286:891–892.
   PubMed Web of Science ®Google Scholar
• GOLDRING MB: Degradation of articular cartilage in culture: Regulatory factors. In: Joint Cartilage Degradation: Basic and Clinical Aspects. Woessner JF Jr., Howell DS (Eds.), Marcel Dekker, Inc., New York (1993):281–345.
   Google Scholar
• WESTACOTT CI, SHARIF M: Cytokines in osteoarthritis: mediators or markers of joint destruction? Sem. Arthritis Rheum. (1996) 25:254–272.
   Web of Science ®Google Scholar
• AMIN AR, DAVE M, ATTUR M, ABRAMSON SB: COX-2, NO, and cartilage damage and repair. Curc Rheumatal. Rep. (2000) 2:447–453.
   PubMedGoogle Scholar
• ATTUR MG, DAVE M, CIPOLLETTA C etal.: Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by Type II IL-1 decoy receptor. Potential for pharmacological intervention. J. Biol. Chem. (2000) 275:40307–40315.
   Google Scholar
• DINARELLO CA: IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J. Allergy arr. Immunal (1999) 103:11–24.
   PubMed Web of Science ®Google Scholar
• DAYER JM: Interleukin-18, rheumatoid arthritis, and tissue destruction. J. Ohl Invest. (1999) 104:1337–1339.
   PubMed Web of Science ®Google Scholar
• SAHA N, MOLDOVAN F, TARDIF G, PELLETIER JP, CLOUTIER JM, MARTEL-PELLETIER J: Interleukin- lb-converting enzyme/caspase-1 in human osteoarthritic tissues: localization and role in the maturation of interleukin- lb and interleukin-18. Arthritis Rheum. (1999) 42:1577–1587.
   PubMed Web of Science ®Google Scholar
• CHABAUD M, DURAND JM, BUCHS N, FOSSIEZ F, PAGE G, FRAPPART L, MIOSSEC P: Human interleukin-17: AT cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. (1999) 42:963–970.
   PubMed Web of Science ®Google Scholar
• SHALOM-BARAK T, QUACH J, LOTZ M: Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-icB. J. Biol. Chem. (1998) 273:27467–27473.
   PubMed Web of Science ®Google Scholar
• OLEE T, HASHIMOTO S, QUACH J, LOTZ M: IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J. Immunal (1999) 162:1096–1100.
   PubMed Web of Science ®Google Scholar
• DUDLER J, RENGGLI-ZULLIGER N, BUSSO N, LOTZ M, SO A: Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann. Rheum. Dis. (2000) 59:529–532.
   PubMed Web of Science ®Google Scholar
• LUBBERTS E, JOOSTEN LAB, VAN DE LOO FAJ, VAN DEN BERSSELAAR LAM, VAN DEN BERG WB: Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum. (2000) 43:1300–1306.
   PubMed Web of Science ®Google Scholar
• ALAAEDDINE N, DI BATTISTA JA, PELLETIER JP, KIANSA K, CLOUTIER JM, MARTEL-PELLETIER J: Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways. Arthritis Rheum. (1999) 42:710–718.
   PubMed Web of Science ®Google Scholar
• SCHLAAK JF, PFERS I, MEYER ZUM BUSCHENFELDE KH, MARKER-HERMANN E: Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. Gun. Exp. Rheumatol. (1996) 14:155–162.
   PubMed Web of Science ®Google Scholar
• WOODS JM, HAINES GK, SHAH MR, RAYAN G, KOCH AE: Low-level production of interleukin-13 in synovial fluid and tissue from patients with arthritis. Gun. Immun. Immunopath. (1997) 85:210–220.
   PubMed Web of Science ®Google Scholar
• TRONTZAS P, KAMPER EF, POTAMIANOU A, KYRIAZIS NC, KRITIKOS H, STAVRIDIS J: Comparative study of serum and synovial fluid interleukin-11 levels in patients with various arthritides. Clin. Biochem. (1998) 31:673–679.
   PubMed Web of Science ®Google Scholar
• MOOS V, FICKERT S, MULLER B, WEBER U, SIEPER J: Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. Rheumatol. (1999) 26:870–879.
   Web of Science ®Google Scholar
• ALAAEDDINE N, DI BATTISTA JA, PELLETIER JP, KIANSA K, CLOUTIER JM, MARTEL-PELLETIER J: Differential effects of IL-8, LIF (pro-inflammatory) and IL-11 (anti-inflammatory) on TNF-alpha-induced PGE(2)release and on signalling pathways in human OA synovial fibroblasts. Cytokine (1999) 11:1020–1030.
   PubMed Web of Science ®Google Scholar
• AREND WP, GABAY C: Physiologic role of interleukin-1 receptor antagonist. Arthritis Res. (2000) 2:245–248.
   PubMedGoogle Scholar
• REDDI AH: Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN. Arthritis Res. (2001) 3:1–5.
   PubMedGoogle Scholar
• BARNES GL, KOSTENUIK PJ, GERSTENFELD LC, EINHORN TA: Growth factor regulation of fracture repair. J. Bone. Miner Res. (1999) 14:1805–1815.
   PubMed Web of Science ®Google Scholar
• VAN DEN BERG WB: Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res. (2001) 3:18–26.
   PubMedGoogle Scholar
• PELLETIER J-P, CARON JP, EVANS C et al.: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. (1997) 40:1012–1019.
   PubMed Web of Science ®Google Scholar
• CARON JP, FERNANDES JC, MARTEL-PELLETIER J et al.: Chondroprotective effect of intraarticular injections ofinterleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum. (1996) 39:1535–1544.
   Google Scholar
• VAN DEN BERG WB: Lessons for joint destruction from animal models. Curr. Opin. Rheumatol. (1997) 9:221–228.
   PubMedGoogle Scholar
• HIRSCH E, IRIKURA VM, PAUL SM, HIRSH D: Functions of interleukin 1 receptor antagonist in gene knockout and overproducing mice. Proc. Nati Acad. Sci. USA (1996) 93:11008–11013.
   PubMed Web of Science ®Google Scholar
• HORAI R, SAIJO S, TANIOKA J et al.: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. j Esp. Med. (2000) 191:313–320.
   Google Scholar
• JOOSTEN LA, HELSEN MM, SAXNE T et al.: IL-14 blockade prevents cartilage and bone destruction in murine Type II collagen-induced arthritis, whereas TNF-a blockade only ameliorates joint inflammation. j Immunol. (1999) 163:5049–5055.
   PubMed Web of Science ®Google Scholar
• BENDELE AM, CHLIPALA ES, SCHERRER J et al.: Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor Type I in animal models of rheumatoid arthritis. Arthritis Rheum. (2000) 43:2648–2659.
   PubMed Web of Science ®Google Scholar
• WALMSLEY M, KATSIKIS PD, ABNEY E et al.: Interleukin-10 inhibition of the progression of established collagen- induced arthritis. Arthritis Rheum. (1996) 39:495–503.
   PubMed Web of Science ®Google Scholar
• LUBBERTS E, JOOSTEN LA, VAN DEN BERSSELAAR L et al.: Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. j Immunol. (1999) 163:4546–4556.
   Google Scholar
• LUBBERTS E, JOOSTEN LA, VAN DEN BERSSELAAR L et al.: Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin. Esp. Immunol. (2000) 120:375–383.
   Google Scholar
• VAN ROON JAG, LAFEBER FPJG, BIJLSMA JWJ: Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. (2001) 44:3–12.
   PubMed Web of Science ®Google Scholar
• WALMSLEY M, BUTLER DM, MARINOVA-MUTAFCHIEVA L, FELDMANN M: An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis. Immunology (1998) 95:31–37.
   PubMed Web of Science ®Google Scholar
• MULLER-LADNER U, EVANS CH, FRANKLIN BN et al.: Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model. Arthritis Rheum. (1999) 42:490–497.
   PubMed Web of Science ®Google Scholar
• WHALEN JD, LECHMAN EL, CARLOS CA etal.: Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. j Immunol. (1999) 162:3625–3632.
   Google Scholar
• LECHMAN ER, JAFFURS D, GHIVIZZANI SC et al.: Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. j Immunol. (1999) 163:2202–2208.
   PubMed Web of Science ®Google Scholar
• PELLETIER JP, JOVANOVIC DV, LASCAU-COMAN V et al.: Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthritis Rheum. (2000) 43:1290–1299.
   PubMed Web of Science ®Google Scholar
• LEE D, LONG SA, ADAMS JL et al.: Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. I Biol. Chem. (2000) 275:16007–16014.
   Web of Science ®Google Scholar
• HENROTIN YE, ZHENG SX, DEBY GP etal.: Nitric oxide downregulates interleukin lbetalbeta) stimulated IL-6, IL-8, and prostaglandin E2 production by human chondrocytes. I Rheumatol. (1998) 25:1595–1601.
   Google Scholar
• SHAW T, NIXON JS, BOTTOMLEY KM: Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Expert Opin. Investig. Drugs (2000) 9:1469–1478.
   PubMed Web of Science ®Google Scholar
• DAHLBERG L, BILLINGHURST RC, MANNER P et al.: Selective enhancement of collagenase-mediated cleavage of resident Type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1). Arthritis Rheum. (2000) 43:673–682.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates the use of selective MMP inhibitors and epitope- specific antibodies for analysing mechanisms of OA cartilage degradation.
   Google Scholar
• MIX KS, MENGSHOL J, BENBOW U, VINCENTI MP, SPORN MB, BRINCKERHOFF CE: A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. (2001) 44:1096–1104.
   PubMed Web of Science ®Google Scholar
• NEUHOLD LA, KILLAR L, ZHAO W et al.: Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. 1. Chi]. Invest. (2001) 107:35–44.
   Google Scholar
• ••First demonstration in vivo of the criticalrole of MMP-13 in osteoarthritis.
   Google Scholar
• TORTORELLA MD, BURN TC, PRATTA MA et al.: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 284: 1664-1666.
   Google Scholar
• ABBASZADE I, LIU RQ, YANG F et al.: Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. I Biol. Chem. (1999) 274:23443–23450.
   Web of Science ®Google Scholar
• LEWIS AJ, MANNING AM: New targets for anti-inflammatory drugs. Curr. Opin. Chem. Biol. (1999) 3:489–494.
   PubMed Web of Science ®Google Scholar
• BADGER AM, GRISWOLD DE, KAPADIA R et al.: Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. (2000) 43:175–183.
   PubMed Web of Science ®Google Scholar
• FOXWELL BMJ, BONDESON J, BRENNAN E FELDMANN M: Adenoviral transgene delivery provides an approach to indentifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFicB in tumour necrosis factor production. Ann. Rheum. Dis. (2000) 59(Suppl.
   Google Scholar
• MAKAROV SS: NF-icB as a therapeutic target in chronic inflammation: recent advances. Malec. Med. Today (2000) 6:441–448.
   PubMedGoogle Scholar
• EVANS CH, ROBBINS PD,
   Google Scholar
• GHIVIZZANI SC et al.: Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Human Gene Therapy (1996) 7:1261–1280.
   PubMed Web of Science ®Google Scholar
• EVANS CH, GHIVIZZANI SC, KANG R et al.: Gene therapy for rheumatic diseases. Arthritis Rheum. (1999) 42:1–16.
   PubMed Web of Science ®Google Scholar
• MAINI RN, TAYLOR PC: Anti-cytokine therapy for rheumatoid arthritis. Ann. Rev Med. (2000) 51:207–229.
   PubMed Web of Science ®Google Scholar
• ••Up-to-date and comprehensive review ofanti-cytokine therapy for rheumatoid arthritis.
   Google Scholar
• TAK PP, BRESNIHAN B: The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum. (2000) 43:2619–2633.
   PubMed Web of Science ®Google Scholar
• CAMPION GV, LEBSACK ME, LOOKABAUGH J, GORDON G, CATALANO M: Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum. (1996) 39:1092–1101.
   Google Scholar
• BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196–2204.
   PubMed Web of Science ®Google Scholar
• JIANG Y, GENANT HK, WATT I, COBBY M, BRESNIHAN B, AITCHISON R, MCCABE D: A multicenter, double-blind, dose-ranging, randomized, placebo- controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. (2000) 43:1001–1009.
   PubMed Web of Science ®Google Scholar
• DREVLOW BE, LOVIS R, HAAG MA et al.: Recombinant human interleukin-1 receptor Type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. (1996) 39:257–265.
   PubMed Web of Science ®Google Scholar
• AREND WP, MALYAK M, SMITH ME JR. et al.: Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. 1. Immurrof (1994) 153:4766–4774.
   Google Scholar
• VAN DEN BERG WB: Arguments for interleukin 1 as a target in chronic arthritis. Ann. Rheum. Dis. (2000) 59\(Suppl. 1):i81–
   Google Scholar
• ••Van den Berg provides a persuasiveargument for the critical role of IL-1 in cartilage erosion.
   Google Scholar
• NELSON FC, ZASK A: The therapeutic potential of small molecule TACE inhibitors. Expert Opin. Investig. Drugs (1999) 8:383–392.
   PubMedGoogle Scholar
• RADIN EL: Subchondral bone changes andcartilage damage. Equine Vet. 1 (1999) 31:94–95.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ RW: Bone remodeling in osteoarthritis: subchondral and osteophytic responses. Osteoarthritis Cartilage (1999) 7:323–324.
   PubMed Web of Science ®Google Scholar
• WESTACOTT CI, WEBB GR, WARNOCK MG, SIMS JV, ELSON CJ: Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum. (1997) 40:1282–1291.
   PubMed Web of Science ®Google Scholar
• GRAVALLESE EM, GALSON DL, GOLDRING SR, AURON PE: The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res. (2001) 3:6–12.
   PubMedGoogle Scholar
• ••Timely review of signalling by TNF-receptor family members, including RANKL, and their role in bone resorption.
   Google Scholar
• KONG YY, FEIGE U, SAROSI I etal.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 402:304–309.
   Google Scholar
• KOMURO H, OLEE T, QUACH J et al.: The RANK/RANKUOPG system in cartilage. Osteoarthritis Cartilage (2000) 8(Suppl.R537.
   Google Scholar
• SCHWARZ EM, LOONEY RJ, O'KEEFE RJ: Anti-TNF-a therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res. (2000) 2:165–168.
   PubMedGoogle Scholar
• EVANS CH, ROBBINS PD, GHIVIZZANI SC et al.: Results from the first human clinical trial of gene therapy for arthritis. Arthritis Rheum. (1999) 44(Suppl.):S170.
   Google Scholar
• TOMITA T, HASHIMOTO H, TOMITA N et al.: In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendai virus) and liposomes. Arthritis Rheum. (1997) 40:901–906.
   PubMed Web of Science ®Google Scholar
• GHIVIZZANI SC, LECHMAN ER, KANG R etal.: Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor a soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc. Nati Acad. Sri. USA (1998) 95:4613–4618.
   Google Scholar
• KIM SH, EVANS CH, KIM S, OLIGINO T, GHIVIZZANI SC, ROBBINS PD: Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res. (2000) 2:293–302.
   PubMedGoogle Scholar
• EVANS CH, ROBBINS PD: Potential treatment of osteoarthritis by gene therapy. Rheum. Dis. Clin. North Am. (1999) 25:333–344.
   PubMed Web of Science ®Google Scholar
• SMITH P, SHULER FD, GEORGESCU et al.: Genetic enhancement of matrix synthesis by articular chondrocytes: comparison of different growth factor genes in the presence and absence of interleukin-I. Arthritis Rheum. (2000) 43:1156–1164.
   PubMed Web of Science ®Google Scholar
• SOLCHAGA LA, DENNIS JE, GOLDBERG VM, CAPLAN AT: Hyaluronic acid-based polymers as cell carriers for tissue-engineered repair of bone and cartilage. j Orthop. Res. (1999) 17:205–213.
   PubMed Web of Science ®Google Scholar
• Y00 JU, BARTHEL TS, NISHIMURA K, SOLCHAGA L, CAPLAN AT, GOLDBERG VM, JOHNSTONE B: The chondrogenic potential of human bone-marrow-derived mesenchymal progenitor cells. J. Boric...Joint Sorg. -Am. (1998) 80:1745–1757.
   PubMedGoogle Scholar